Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 10:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 102 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Docosahexaenoic Acid Clear all
Not listed Phase 2 Interventional

An Open-Label Study of Vascazen in Cardiac Rehab Patients With Deficient Blood Omega-3 Fatty Acid Levels

NCT02052986
View directory record Official record
Conditions
Dyslipidemia
Interventions
VASCAZEN
Other
Lead sponsor
New York Hospital Queens
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Fresh Meadows, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2014 · Synced Sep 20, 2026, 10:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects

NCT01486433
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Simvastatin, acetylsalicylic acid (ASA), omefas
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Sep 20, 2026, 10:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Growth and Adiposity in Newborns: The Influence of Prenatal Docosahexaenoic Acid (DHA) Supplementation

NCT03310983
View directory record Official record
Conditions
Pregnancy; Nutritional Diseases
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 20, 2026, 10:16 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A

NCT00000116
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Vitamin A, Docosahexaenoic acid, Control fatty acid
Dietary Supplement
Lead sponsor
Carol Weigel DiFranco
NIH
Eligibility
18 Years to 55 Years
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2002
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Sep 20, 2026, 10:16 PM EDT
Completed Not applicable Interventional

Use of Formula Fortified With DHA in Infants With Cystic Fibrosis

NCT00530244
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Docosahexaenoic acid (DHA), Standard formula (Enfamil)
Dietary Supplement
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
Up to 56 Days
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
24
States / cities
Birmingham, Alabama • Atlanta, Georgia • Des Moines, Iowa + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Sep 20, 2026, 10:16 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Commerical DHA Supplementation

NCT05415293
View directory record Official record
Conditions
Randomized Clinical Trial, Docosahexaenoic Acid, Pregnancy
Interventions
Expecta 200mg DHA, Promise 275mg DHA
Dietary Supplement
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Sep 20, 2026, 10:16 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia

NCT00815685
View directory record Official record
Conditions
Cancer Cachexia
Interventions
Eicosapentaenoic Acid
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
25 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Stuart, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 20, 2026, 10:16 PM EDT
Completed Phase 2 Interventional

Use of Omega-3 Fatty Acids for Perinatal Depression

NCT00402389
View directory record Official record
Conditions
Depression, Depression, Postpartum
Interventions
Omega-3 Fatty Acids (EPA plus DHA), Supportive psychotherapy, Placebo
Drug · Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Sep 20, 2026, 10:16 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults

NCT07392723
View directory record Official record
Conditions
Cognitive Dysfunction, Alzheimer Disease, Blood-Brain Barrier, Apolipoprotein E, Deficiency or Defect of, Brain Aging, Fatty Acids, Omega-3
Interventions
Alpha-Linolenic Acid (2.6 g/day), Placebo Control Group
Drug · Dietary Supplement
Lead sponsor
Michal Schnaider Beeri, Ph.D.
Other
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 20, 2026, 10:16 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

DHA Supplementation for Lactating Mothers

NCT01732874
View directory record Official record
Conditions
Docosohexaenoic Acid Supplementation of Mothers to
Interventions
Expecta 200 mg, Expecta 1 gram
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 45 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 20, 2026, 10:16 PM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole

NCT01478477
View directory record Official record
Conditions
Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
omega-3 fatty acid supplement, Placebo, Clinical assessments, Assessment of therapy complications, Magnetic Resonance Imaging, Correlative/special studies
Dietary Supplement · Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2023 · Synced Sep 20, 2026, 10:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Understanding Fish Consumption Habits During Pregnancy

NCT01178398
View directory record Official record
Conditions
Nutrition
Interventions
Not listed
Lead sponsor
Harvard Pilgrim Health Care
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 20, 2026, 10:16 PM EDT
Completed Phase 2 Interventional Results available

DHA and X-Linked Retinitis Pigmentosa

NCT00100230
View directory record Official record
Conditions
Retinitis Pigmentosa, X-linked Genetic Diseases
Interventions
docosahexaenoic acid OR corn/soy oil placebo
Drug
Lead sponsor
Retina Foundation of the Southwest
Other
Eligibility
7 Years to 32 Years · Male only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Sep 20, 2026, 10:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Fish Oil Supplementation on the Brain Health of Collegiate Football Athletes

NCT04796207
View directory record Official record
Conditions
Traumatic Brain Injury (TBI), Chronic Traumatic Encephalopathy (CTE)
Interventions
Fish Oil (DPA+EPA 2:1 ratio) Capsules, High Oleic Safflower Oil Capsules
Dietary Supplement
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 25 Years · Male only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Sep 20, 2026, 10:16 PM EDT
Recruiting Early Phase 1 Interventional

Differential Thrombogenesis by EPA and DHA Mediated by HDL

NCT06494488
View directory record Official record
Conditions
Lipid Metabolism Disorders, Hypertriglyceridemia
Interventions
EPA, DHA
Drug
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 69 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 20, 2026, 10:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hallelujah Acres Omega 3 Fat Study

NCT01517685
View directory record Official record
Conditions
Omega 3 Fat Status
Interventions
Organic flax seed oil, fish oil
Dietary Supplement
Lead sponsor
Hallelujah Acres
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Zillah, Washington
Source: ClinicalTrials.gov public record
Updated Feb 18, 2016 · Synced Sep 20, 2026, 10:16 PM EDT
Not listed Phase 2 Interventional

A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD)

NCT01202812
View directory record Official record
Conditions
Sickle Cell Disease, HEMOGLOBIN SS, Hemoglobin S Beta-0 Thalassemia, Inflammation, Quality of Life
Interventions
Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA), Placebo Capsules
Dietary Supplement · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
10 Years to 19 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 24, 2010 · Synced Sep 20, 2026, 10:16 PM EDT
Not listed Not applicable Interventional

Study of Moderate Dose Omega 3 Fatty Acid Supplement in Premenopausal Women at High Risk for Breast Cancer

NCT03383835
View directory record Official record
Conditions
Breast Cancer
Interventions
Omega-3 Supplementation
Dietary Supplement
Lead sponsor
Lauren Nye
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Sep 20, 2026, 10:16 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effect of Fish Oil on Athlete's Executive Function

NCT04570995
View directory record Official record
Conditions
Brain Health, Brain Function, Brain Development
Interventions
Fish Oil, Safflower Oil
Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Sep 20, 2026, 10:16 PM EDT
Completed Phase 3 Interventional Results available

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

NCT01047501
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
80
States / cities
Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 20, 2026, 10:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Docosahexaenoic Acid Supplementation on Biomarkers of Concussion Over the Course of a Year in Canadian National Rugby Players

NCT03582267
View directory record Official record
Conditions
Head Trauma
Interventions
Docosahexaenoic Acid (DHA)
Dietary Supplement
Lead sponsor
Texas Christian University
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Sep 20, 2026, 10:16 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

AlmegaPL CV Health Open Label Study

NCT05267301
View directory record Official record
Conditions
Cholesterol, Triglycerides, Omega-3, Eicosapentaenoic Acid
Interventions
AlmegaPL (FDA NDIN # 826)
Dietary Supplement
Lead sponsor
Qualitas Health
Industry
Eligibility
18 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Tempe, Arizona • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Sep 20, 2026, 10:16 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation

NCT01208961
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Epanova (4 g) and Lovaza (4 g), Lovaza (4 g) and Epanova (4 g)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 14, 2015 · Synced Sep 20, 2026, 10:16 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach

NCT02553915
View directory record Official record
Conditions
Major Depressive Disorder, Overweight, Inflammation
Interventions
Placebo, EPA 1 g/day, EPA 2 g/day, EPA 4 g/day
Other · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2022 · Synced Sep 20, 2026, 10:16 PM EDT